Trump order could fast-track review of psychedelic ibogaine. What is it?
Summary
President Donald Trump signed an executive order to speed up the review process for psychedelic drugs, including ibogaine. This order aims to make it faster to study and potentially approve these substances for medical use.Key Facts
- President Trump signed the executive order on a Saturday.
- The focus is on psychedelic drugs, which affect perception and mood.
- Ibogaine is one of the psychedelic drugs mentioned.
- The order aims to speed up drug reviews by government agencies.
- Faster reviews could help new medicines reach patients sooner.
- Psychedelic drugs are being studied for potential treatment of mental health conditions.
- The government usually takes a long time to review drugs for safety and effectiveness.
- This order signals more support for researching new therapies using psychedelics.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
